Systemic atrophies primarily affecting the central nervous system

G6_NEUATR

Endpoint definition

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 G10-G13
  • Cause of death: ICD-10 G10-G13

2 out of 7 registries used, show all original rules.

1631

4. Check minimum number of events

None

1631

5. Include endpoints

1837

6. Filter based on genotype QC (FinnGen only)

1649

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
2
First used in FinnGen datafreeze
DF2

Case counts by codes

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 16815 7755 8724
Only index persons 10265 4914 5351
Unadjusted period prevalence (%)
Whole population 0.24 0.22 0.24
Only index persons 0.19 0.18 0.20
Median age at first event (years)
Whole population 61.80 62.97 60.68
Only index persons 60.13 60.86 59.47

-FinnGen-

Key figures

All Female Male
Number of individuals 1649 719 930
Unadjusted period prevalence (%) 0.35 0.26 0.43
Median age at first event (years) 63.05 61.03 64.62

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
1694
Matched controls
16940
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
JDB10
NOMESCO Finland
Percutaneous gastrostomy
31.3
311.1
207
75
R47.1
ICD-10 Finland
Dysarthria and anarthria
34.9
308.5
198
64
N99
ICPC
Neurological disease other
52.9
307.7
319
74
G12.2
ICD-10 Finland
Motor neuron disease
14263.2
307.7
794
*
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
30.5
307.7
255
98
J96.1
ICD-10 Finland
Chronic respiratory failure
16.0
283.1
255
185
N28
ICPC
Limited function/disability (N)
18.9
260.2
213
128
G11.9
ICD-10 Finland
Hereditary ataxia, unspecified
+∞
248.2
232
*
N07XX02
ATC
riluzole; oral
+∞
238.3
223
*
R27.0
ICD-10 Finland
Ataxia, unspecified
48.3
199.9
117
26
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.2
193.3
385
762
G12.9
ICD-10 Finland
Spinal muscular atrophy, unspecified
+∞
162.1
153
*
R4130
NOMESCO Finland
Speech therapy
10.5
158.7
184
195
G11.2
ICD-10 Finland
Late-onset cerebellar ataxia
+∞
139.5
132
*
M03BX01
ATC
baclofen; systemic
12.3
133.3
136
119
Z51.5
ICD-10 Finland
Palliative care
4.4
127.6
380
1037
TAB00
NOMESCO Finland
Lumbar puncture
6.9
126.8
211
343
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
7.0
126.4
207
331
R13
ICD-10 Finland
Dysphagia
5.0
122.8
304
715
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.9
121.5
237
451
Z31.5
ICD-10 Finland
Genetic counselling
6.8
118.5
199
326
G12.8
ICD-10 Finland
Other spinal muscular atrophies and related syndromes
+∞
107.4
102
*
N29
ICPC
Neurological sympt/complt other
9.5
97.4
119
134
N03AE01
ATC
clonazepam; systemic
5.1
94.5
219
483
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
8.0
93.0
131
176
B91
ICD-10 Finland
Sequelae of poliomyelitis
31.6
88.8
58
19
TJD20
NOMESCO Finland
Change of gastrostomy tube
29.1
88.0
59
21
G11.8
ICD-10 Finland
Other hereditary ataxias
+∞
84.1
80
*
G72.9
ICD-10 Finland
Myopathy, unspecified
14.0
84.0
78
58
L28
ICPC
Limited function/disability (L)
2.9
82.8
536
2336
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.7
79.5
289
891
R1250
NOMESCO Finland
Evaluation of functional capability
7.0
79.3
125
190
1380A
ICD-9 Finland
Late effects of acute poliomyelitis[SEQUELAE POLIOMYELITIDIS]
+∞
76.6
73
*
G12.1
ICD-10 Finland
Other inherited spinal muscular atrophy
706.3
69.6
68
*
A28
ICPC
Limited function/disability NOS
2.7
69.3
511
2351
SPAT1229
SPAT
Assessment of need for aid
3.5
63.4
242
765
WX725
NOMESCO Finland
Noninvasive ventilation
4.0
61.1
186
503
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.9
60.3
191
531
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
5.7
57.3
111
207
NXL00
NOMESCO Finland
Biopsy of muscle
21.0
56.7
43
21
N18
ICPC
Paralysis/weakness
6.1
55.8
100
173
N02AA01
ATC
morphine; systemic, rectal
6.1
53.6
96
166
R25.3
ICD-10 Finland
Fasciculation
22.2
52.6
39
18
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.4
52.4
210
681
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.3
52.1
223
753
N19
ICPC
Speech disorder
8.0
52.1
72
94
R26.0
ICD-10 Finland
Ataxic gait
22.8
51.9
38
17
R4120
NOMESCO Finland
Occupational therapy
3.6
51.8
188
572
G11.4
ICD-10 Finland
Hereditary spastic paraplegia
+∞
49.2
47
*
XG466
NOMESCO Finland
Sleep oxymetry
4.8
46.2
109
241
G10
ICD-10 Finland
Huntington disease
+∞
46.0
44
*
JC2KB
NOMESCO Finland
Functional X-ray examination of swallowing
8.3
45.0
60
75
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.6
44.8
318
1404
R1260
NOMESCO Finland
Evaluation of communicative skills
6.2
44.8
78
131
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.2
44.6
124
312
R4190
NOMESCO Finland
Nutritional therapy
4.1
43.2
125
324
D21
ICPC
Swallowing problem
6.5
42.6
71
114
R47.8
ICD-10 Finland
Other and unspecified speech disturbances
8.0
41.0
56
72
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
37.8
365
1836
R5599
NOMESCO Finland
Other rehabilitation service
4.5
36.9
93
217
F80.1
ICD-10 Finland
Expressive language disorder
9.2
36.1
44
49
SPAT1215
SPAT
Assessment of need for medical rehabilitation
3.7
34.3
111
311
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
4.7
34.3
80
175
SPAT1231
SPAT
Assessment of adjustments needed in living environment
4.9
33.4
74
155
R5110, ,
SPAT
2.5
30.9
212
912
G31.0
ICD-10 Finland
Circumscribed brain atrophy
9.9
29.5
34
35
34899
ICD-8 Finland
Motor neurone disease, Other and unspecified manifestations
+∞
29.2
28
*
UDQ42
NOMESCO Finland
Endoscopic assessment of swallowing function
28.5
29.0
39
14
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
4.1
27.8
77
193
XA402
NOMESCO Finland
ENMG
4.5
27.8
69
159
G31.9
ICD-10 Finland
Degenerative disease of nervous system, unspecified
24.3
27.0
38
16
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
5.9
26.3
47
81
XG416
NOMESCO Finland
Measurement of maximal airway pressure
+∞
26.1
25
*
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
7.4
25.5
37
51
SPAT1297
SPAT
Other function in accordance with speech therapy nomenclature
10.5
25.4
28
27
R4120, ,
SPAT
5.5
25.0
49
92
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
4.4
24.8
63
148
OAB74
NOMESCO Finland
Nutritional guidance related to treatment and rehabilitation for medical condition
6.3
24.5
41
66
3342A
ICD-9 Finland
Spinocerebellar disease, Primary cerebellar degeneration
+∞
23.0
22
*
Z50.5
ICD-10 Finland
Speech therapy
5.4
22.8
45
85
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.1
22.7
96
319
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
1.8
21.8
397
2447
04499
ICD-8 Finland
Late effects of actue poliomyelitis
222.8
21.6
22
*
G62.8
ICD-10 Finland
Other specified polyneuropathies
5.8
21.5
39
68
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
2.5
21.1
145
622
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
2.5
20.8
133
551
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
2.3
20.7
174
814
N03AX12
ATC
[U] gabapentin; oral
1.9
20.7
301
1726
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
4.8
20.6
47
101
GX2D5
NOMESCO Finland
Sleep oximetry
8.1
20.0
27
34
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
5.4
20.0
39
73
G35
ICD-10 Finland
Multiple sclerosis
5.7
20.0
37
66
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.4
19.7
143
628
Z82.0
ICD-10 Finland
Family history of epilepsy and other diseases of the nervous system
26.4
19.1
26
10
XG467
NOMESCO Finland
Nocturnal CO2 monitoring
34.7
18.9
24
7
G12.0
ICD-10 Finland
Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]
+∞
18.8
18
*
SPAT1216
SPAT
Assessment of functional ability
1.8
18.3
307
1836
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
2.3
18.1
150
698
XA800
NOMESCO Finland
Neuropsychological investigation
2.8
18.0
90
329
R26.2
ICD-10 Finland
Difficulty in walking, not elsewhere classified
4.3
17.9
46
109
G11.18
ICD-10 Finland
Early-onset cerebellar ataxia
181.8
17.5
18
*
WPA13
NOMESCO Finland
Palliative consultation
7.8
17.4
24
31
N70
ICPC
Poliomyelitis
42.5
17.3
21
5
Z50.1
ICD-10 Finland
Other physical therapy
2.5
17.2
115
487
XX9TE
NOMESCO Finland
Compementary ultrasound examination
7.2
17.0
25
35
L99
ICPC
Musculoskeletal disease other
3.6
16.9
55
155
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
5.9
16.2
29
50
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
15.5
16.2
26
17
M62.5
ICD-10 Finland
Muscle wasting and atrophy, not elsewhere classified
21.2
16.0
23
11
JDB01
NOMESCO Finland
Laparoscopic gastrostomy
60.6
15.8
18
*
L19
ICPC
Muscle symptom/complaint NOS
3.2
15.7
61
193
UDQ12
NOMESCO Finland
Flexible laryngoscopy
2.3
15.7
116
514
3352A
ICD-9 Finland
Anterior horn cell disease, Motor neuron disease[SCLEROSIS LATERALIS AMYOTROPHICA]
+∞
15.6
15
*
G57.3
ICD-10 Finland
Lesion of lateral popliteal nerve
4.2
15.6
41
99
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.6
15.2
561
4094
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
5.3
15.2
30
57
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.6
15.1
514
3683
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.8
15.0
275
1683
T05
ICPC
Feeding problem of adult
5.2
14.9
30
58
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.6
14.8
500
3574
OAB73
NOMESCO Finland
Prevention and treatment of malnutrition
4.9
14.8
32
66
N02AA05
ATC
oxycodone; systemic
1.6
14.6
364
2417
G11.00
ICD-10 Finland
Cerebellar dysplasia and aplasia
+∞
14.6
14
*
SPAT1222
SPAT
Counselling/guidance promoting independent living
1.7
14.6
282
1750
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
4.3
14.6
37
87
G71.08
ICD-10 Finland
Other muscular dystrophy
36.4
14.4
18
5
A98
ICPC
Health maint/preventive medicine
0.6
14.3
1336
14562
G60.0
ICD-10 Finland
Hereditary motor and sensory neuropathy
17.1
14.3
22
13
XW5WT
NOMESCO Finland
Other blood specimen with radiologicl guidance
27.4
14.3
19
7
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
14.6
14.1
23
16
N05BA06
ATC
lorazepam; systemic, sublingual
2.3
13.7
108
491
WX781
NOMESCO Finland
Remote monitoring, noninvasive ventilation
34.3
13.5
17
5
RS314, ,
NOMESCO Finland
26.0
13.4
18
7
G82.1
ICD-10 Finland
Spastic paraplegia
40.4
13.2
16
*
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
5.5
13.1
25
46
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
11.1
12.5
23
21
3343A
ICD-9 Finland
Spinocerebellar disease, Other cerebellar ataxia
+∞
12.5
12
*
G11.02
ICD-10 Finland
Dysequilibrium syndrome
+∞
12.5
12
*
Z3229
NOMESCO Finland
Other healthcare associate professional
1.9
12.5
156
846
GX1P5
NOMESCO Finland
Nocturnal CO2 monitoring
130.9
12.4
13
*
G71.3
ICD-10 Finland
Mitochondrial myopathy, not elsewhere classified
37.8
12.2
15
*
SPAT1234
SPAT
Support of social functional capacity
2.2
12.1
106
504
M54.1
ICD-10 Finland
Radiculopathy
2.5
12.1
75
307
RS340, ,
NOMESCO Finland
26.9
12.0
16
6
R1100
NOMESCO Finland
General evaluation of the need for rehabilitation
3.7
12.0
37
101
G31.2
ICD-10 Finland
Degeneration of nervous system due to alcohol
4.9
11.9
26
54
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
3.7
11.6
37
103
G11
ICD-10 Finland
Hereditary ataxia
+∞
11.5
11
*
3351X
ICD-9 Finland
Anterior horn cell disease, Spinal muscular atrophy[ATROPHIA MUSCULORUM SPINALIS NUD]
+∞
11.5
11
*
G13.0
ICD-10 Finland
Paraneoplastic neuromyopathy and neuropathy
+∞
11.5
11
*
Z02.4
ICD-10 Finland
Examination for driving licence
0.6
11.4
265
3902
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.5
11.2
459
3383
ABC60
NOMESCO Finland
Decompression of cervical spinal cord
4.8
11.2
25
53
N05BA04
ATC
oxazepam; oral
1.5
11.2
413
2981
SPAT1296
SPAT
Other function in accordance with occupational therapy nomenclature
4.4
11.0
27
62
RS222, ,
NOMESCO Finland
4.1
11.0
30
75
SPAT1167
SPAT
Insertion of urinary catheter
2.4
10.9
72
303
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
3.4
10.9
38
113
N06AA09
ATC
amitriptyline; systemic
1.8
10.8
160
915
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
2.2
10.8
87
400
Z3226
NOMESCO Finland
Physiotherapist
1.6
10.8
296
2000
A06AD11
ATC
lactulose; oral
1.6
10.8
278
1851
WPA42
NOMESCO Finland
Family-centered psychosocial intervention in palliative care
28.2
10.7
14
5
R49.08
ICD-10 Finland
Other specified dysphonia
3.1
10.7
44
145
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
1.8
10.6
177
1049
TNX05
NOMESCO Finland
Simple incision of soft tissue, unspecified region
14.3
10.5
17
12
ABD40
NOMESCO Finland
Implantation of spinal injection device
110.7
10.4
11
*
7812A
ICD-9 Finland
Symptoms involving nervous and musculoskeletal systems, Abnormality of gait
+∞
10.4
10
*
A210_, ,
NOMESCO Finland
+∞
10.4
10
*
3349X
ICD-9 Finland
Spinocerebellar disease, unspecified
+∞
10.4
10
*
A120_, ,
NOMESCO Finland
+∞
10.4
10
*
34898
ICD-8 Finland
Motor neurone disease, Alii definiti
+∞
10.4
10
*
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
7.8
10.4
23
30
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
8.8
10.3
21
24
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
2.3
10.3
75
331
G61.8
ICD-10 Finland
Other inflammatory polyneuropathies
18.9
10.3
15
8
G82.2
ICD-10 Finland
Paraplegia, unspecified
9.6
10.3
20
21
XKD06
NOMESCO Finland
Physiologic investigation of micturition
2.5
10.3
64
263
OAB43, ,
SPAT
0.5
10.2
119
2112
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
3.7
10.2
31
84
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
3.2
10.1
40
129
SPAT1245
SPAT
Provision of support and information to patient’s family members
2.2
9.9
85
402
N81
ICPC
Injury nervous system other
10.7
9.8
18
17
N06AX21
ATC
duloxetine; oral
1.7
9.7
180
1100
WPA15
NOMESCO Finland
Palliative care consultation with the patient and loved ones
5.3
9.6
19
36
WPA43
NOMESCO Finland
A doctor's home visit to perform palliative care
15.1
9.5
15
10
R5140
NOMESCO Finland
Monitoring the use of the aid
1.7
9.5
191
1193
Z01.8
ICD-10 Finland
Other specified special examinations
1.5
9.5
354
2551
F02.29*G10
ICD-10 Finland
Dementia in Huntington's disease without information on additional symptoms
+∞
9.4
9
*
RP120, ,
NOMESCO Finland
+∞
9.4
9
*
RK110, ,
NOMESCO Finland
4.4
9.3
23
53
Z46.9
ICD-10 Finland
Fitting and adjustment of unspecified device
3.5
9.2
31
90
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
4.2
9.2
24
58
J96.9
ICD-10 Finland
Respiratory failure, unspecified
4.4
9.1
22
50
M47.1
ICD-10 Finland
Other spondylosis with myelopathy
3.5
9.1
30
86
RS221, ,
NOMESCO Finland
3.5
9.1
31
91
RS142, ,
NOMESCO Finland
18.7
8.9
13
7
AA1AD
NOMESCO Finland
CT of head and brain
1.4
8.9
497
3854
N03AF01
ATC
carbamazepine; oral, rectal
2.0
8.9
91
460
JDB00
NOMESCO Finland
Gastrostomy
24.1
8.9
12
5
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
3.1
8.8
35
113
E78.0
ICD-10 Finland
Pure hypercholesterolaemia
0.6
8.8
173
2670
G40.9
ICD-10 Finland
Epilepsy, unspecified
2.3
8.7
63
277
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
1.6
8.7
197
1267
N94
ICPC
Peripheral neuritis/neuropathy
14.1
8.7
14
10
M41.4
ICD-10 Finland
Neuromuscular scoliosis
50.2
8.7
10
*
N06AB04
ATC
citalopram; systemic
1.5
8.6
306
2178
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
2.5
8.6
54
223
Z99.8
ICD-10 Finland
Dependence on other enabling machines and devices
16.4
8.6
13
8
R4110
NOMESCO Finland
Physiotherapy
1.4
8.5
439
3352
N05BA01
ATC
diazepam; systemic, rectal
1.6
8.5
206
1347
N04BB01
ATC
amantadine; oral
3.5
8.5
29
85
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
20.1
8.5
12
6
XKC03
NOMESCO Finland
Water cystometry
2.4
8.4
54
225
G04BD12
ATC
mirabegron; oral
1.6
8.4
208
1369
A220_, ,
NOMESCO Finland
+∞
8.3
8
*
G13.2*E03.9
ICD-10 Finland
Systemic atrophy primarily affecting central nervous system in myxoedema
+∞
8.3
8
*
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
2.1
8.2
81
405
N87
ICPC
Parkinsonism
3.1
8.1
33
108
N06AB10
ATC
escitalopram; oral
1.5
8.1
261
1818
WYA20, ,
SPAT
4.6
8.1
19
42
OAA67, ,
SPAT
0.4
8.1
50
1106
Z93.1
ICD-10 Finland
Gastrostomy status
17.3
8.1
12
7
R33
ICD-10 Finland
Retention of urine
1.7
8.0
160
996
XG410
NOMESCO Finland
Flow-volume spirometry
2.1
8.0
72
347
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
10.1
8.0
15
15
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
2.0
8.0
86
443
WPA40
NOMESCO Finland
Individual-centered psychosocial intervention in palliative care
22.1
8.0
11
5
ZY010
NOMESCO Finland
Hospital outpatient
2.1
8.0
74
361
R42
ICD-10 Finland
Dizziness and giddiness
1.4
8.0
368
2752
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
1.7
8.0
136
812
M62.9
ICD-10 Finland
Disorder of muscle, unspecified
9.4
7.8
15
16
Z2446
NOMESCO Finland
Social worker
1.8
7.7
106
593
N06DX01
ATC
memantine; oral
0.4
7.6
39
929
R1420
NOMESCO Finland
Assessment of rehabilitation needs and/or compilation of rehabilitation plan
11.9
7.6
13
11
R25.1
ICD-10 Finland
Tremor, unspecified
2.3
7.5
53
231
R1410
NOMESCO Finland
Drawing up a rehabilitation plan
6.2
7.5
19
31
TKC20, ,
SPAT
4.3
7.5
19
45
N05BA09
ATC
clobazam; oral
6.5
7.4
18
28
R1420, ,
SPAT
6.5
7.4
18
28
R4130, ,
SPAT
7.7
7.4
16
21
34800
ICD-8 Finland
Motor neurone disease, Amyotrophic lateral sclerosis
+∞
7.3
7
*
SPAT1254
SPAT
Administration of medicine
1.5
7.3
235
1638
TNH33
NOMESCO Finland
Custom moulded brace, ankle or foot
3.2
7.3
28
89
Z73.6
ICD-10 Finland
Limitation of activities due to disability
3.9
7.3
21
55
SPAT1262
SPAT
Handing over of treatment supplies
1.5
7.2
275
1980
S12
ICPC
Insect bite/sting
0.4
7.2
36
867
OAA80, ,
SPAT
0.3
7.1
18
602
WPA10, ,
SPAT
8.0
7.1
15
19
R5210
NOMESCO Finland
Assessment of the improvements needed in the living environment
8.0
7.1
15
19
TJD10
NOMESCO Finland
Insertion of other tube into stomach or duodenum
12.1
7.1
12
10
C10AA07
ATC
rosuvastatin; oral
0.7
7.0
319
4180
Z2445
NOMESCO Finland
Psychologist
2.2
6.9
55
253
XA421
NOMESCO Finland
Nocturnal polygraphy
7.6
6.9
15
20
R26
ICD-10 Finland
Abnormalities of gait and mobility
13.8
6.9
11
8
K11.72
ICD-10 Finland
Xerostomia
13.8
6.9
11
8
G72.8
ICD-10 Finland
Other specified myopathies
2.7
6.8
36
137
AA5EN
NOMESCO Finland
Brain reseptor or transprot protein distribution isotope imaging
8.3
6.8
14
17
N04BC05
ATC
pramipexole; oral
1.7
6.8
121
731
N06AX11
ATC
mirtazapine; oral
1.3
6.8
499
4017
G60.9
ICD-10 Finland
Hereditary and idiopathic neuropathy, unspecified
40.2
6.8
8
*
ZX120, ,
SPAT
3.1
6.7
27
88
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
1.9
6.7
81
435
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
3.9
6.7
19
49
U04
ICPC
Incontinence urine
1.8
6.7
102
591
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
2.0
6.7
73
380
GD1AA, ,
SPAT
0.5
6.6
79
1398
R63.4
ICD-10 Finland
Abnormal weight loss
2.0
6.6
70
360
R99
ICD-10 Finland
Other ill-defined and unspecified causes of mortality
2.2
6.6
50
226
RS310, ,
NOMESCO Finland
12.3
6.6
11
9
RT274, ,
NOMESCO Finland
12.3
6.6
11
9
A29
ICPC
General symptom/complaint other
1.5
6.6
220
1544
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
2.0
6.6
66
333
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
1.8
6.6
99
571
G81.9
ICD-10 Finland
Hemiplegia, unspecified
3.4
6.6
23
69
GX1D5
NOMESCO Finland
Flow volume spirometry
8.7
6.6
13
15
N02BF01
ATC
gabapentin; oral
1.6
6.5
157
1025
SPAT1125
SPAT
Stoma care and guidance
2.7
6.5
33
123
WX320
NOMESCO Finland
Spinalanesthesy
0.7
6.4
214
2973
N03AX16
ATC
[U] pregabalin
1.4
6.4
340
2595
N07XX06
ATC
tetrabenazine; oral
70.1
6.4
7
*
RP130, ,
NOMESCO Finland
70.1
6.4
7
*
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
1.9
6.4
73
385
V700A
ICD-9 Finland
General medical examination, Routine general medical examination at a health care facility
2.4
6.4
41
172
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
1.7
6.4
110
660
R4110, ,
SPAT
1.5
6.4
204
1419
R69
ICD-10 Finland
Unknown and unspecified causes of morbidity
2.7
6.3
33
125
WPA44
NOMESCO Finland
Nursing home for palliative care
8.2
6.3
13
16
RS122, ,
NOMESCO Finland
8.2
6.3
13
16
N07AA02
ATC
pyridostigmine; systemic
5.5
6.3
17
31
UJC01
NOMESCO Finland
Scopy of lower throat
3.3
6.3
23
71
M89.6
ICD-10 Finland
Osteopathy after poliomyelitis
+∞
6.3
6
*
A211_, ,
NOMESCO Finland
+∞
6.3
6
*
3348X
ICD-9 Finland
Spinocerebellar disease, Other spinocerebellar diseases
+∞
6.3
6
*
33098
ICD-8 Finland
Hereditary neuromuscular disorders, Alii definiti
+∞
6.3
6
*
A222_, ,
NOMESCO Finland
+∞
6.3
6
*
3350A
ICD-9 Finland
Anterior horn cell disease, Werdnig-Hoffmann disease[MORBUS WERDNIG-HOFFMANN]
+∞
6.3
6
*
H02AB02
ATC
dexamethasone; systemic
0.5
6.2
64
1185
G98
ICD-10 Finland
Other disorders of nervous system, not elsewhere classified
26.8
6.2
8
*
Z99.1
ICD-10 Finland
Dependence on respirator
26.8
6.2
8
*
WPA43, ,
SPAT
7.0
6.2
14
20
RS230, ,
NOMESCO Finland
5.4
6.2
17
32
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
3.4
6.1
21
62
R4160
NOMESCO Finland
Other therapy enhancing rehabilitation
2.8
6.1
29
105
J96.0
ICD-10 Finland
Acute respiratory failure
2.7
6.0
30
111

LabWAS

OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
117
88
14.21
125.59
1.1
1.1
37.19
42.51
mg/l
0.43
99
74
115
85
14.44
124.68
1.1
1.1
270.11
292.82
mg/l
0.37
103
73
209
371
6.29
114.91
1.5
1.4
556.36
579.62
mg/l
0.09
202
348
126
126
10.72
112.70
1.0
1.1
—
—
—
0
0
109
97
11.94
105.38
1.1
1.1
0.09
4.93
nmol/l
1.54
13
17
183
330
6.10
98.64
1.5
1.4
3.76
3.79
mmol/l
0.08
172
310
317
915
4.03
96.92
2.6
2.5
17.93
19.50
au/ml
0.13
19
74
295
824
4.12
94.25
1.4
1.3
49.67
57.68
au/ml
0.22
11
64
87
67
13.63
91.84
1.2
1.1
0.51
0.51
ratio
0.03
53
41
173
317
5.96
91.57
1.6
1.6
531.45
836.65
e6/l
0.25
137
249
172
314
5.98
91.39
1.6
1.5
6.19
58.69
e6/l
1.27
128
239
160
295
5.89
84.00
1.6
1.5
—
—
—
0
0
58
27
22.21
78.30
1.1
1.1
—
—
—
0
0
865
4896
2.57
78.04
2.7
2.2
248.90
225.52
u/l
0.36
831
4630
70
69
10.54
62.91
1.1
1.5
5.49
8.40
u/l
0.60
59
55
290
1194
2.72
47.24
2.1
2.7
—
—
—
0
0
288
1203
2.68
45.48
5.1
4.6
5.60
5.15
kpa
11.69
283
1155
328
1472
2.52
44.64
2.3
3.0
67.74
66.35
g/l
3.36
308
1350
280
1177
2.65
43.55
5.0
4.6
7.41
7.41
ph
0.19
246
987
80
155
5.37
39.50
2.0
1.6
—
—
—
0
0
186
709
2.82
34.64
1.6
2.6
3.48
3.67
g/l
1.05
174
648
186
710
2.82
34.54
1.6
2.6
4.24
4.17
g/l
0.60
175
648
186
710
2.82
34.54
1.6
2.6
6.97
7.36
g/l
2.78
175
648
178
664
2.88
34.50
1.6
2.6
2.50
2.95
g/l
8.97
167
602
72
151
4.94
32.47
2.3
1.6
—
—
—
0
0
43
58
7.58
30.20
1.4
1.3
134.74
110.24
nmol/l
0.32
31
40
157
624
2.67
26.81
1.4
2.7
9.89
10.63
g/l
1.23
144
558
1189
13760
0.54
26.67
5.2
6.1
2.71
2.61
mmol/l
3.39
1064
12700
1151
13428
0.55
26.17
4.7
5.2
1.46
1.43
mmol/l
1.33
1039
12359
1162
13516
0.55
26.04
4.7
5.3
4.61
4.51
mmol/l
2.87
1046
12539
112
379
3.09
25.70
4.8
4.1
—
—
—
0
0
378
5940
0.53
25.26
2.0
2.0
1.38
1.34
mmol/l
0.29
321
4934
152
616
2.61
24.93
1.7
2.1
763.92
521.71
ug/l
0.19
144
584
1131
13158
0.58
23.23
6.6
6.9
39.61
39.88
mmol/mol
0.42
1035
12222
340
1999
1.88
21.77
5.8
7.8
5.68
5.11
kpa
8.70
327
1928
339
2000
1.87
21.44
5.7
7.8
11.08
11.91
kpa
3.21
324
1931
179
851
2.23
20.53
5.4
4.9
—
—
—
0
0
1114
12882
0.61
19.87
4.1
4.5
1.30
1.29
mmol/l
0.14
999
11742
332
1990
1.83
19.81
5.8
7.7
3.07
0.91
mmol/l
16.48
284
1638
332
1996
1.83
19.60
5.9
7.9
7.41
7.41
ph
0.14
223
1131
46
102
4.61
19.44
2.0
2.6
17.43
16.15
%
1.57
46
102
1175
13393
0.60
19.38
5.0
5.4
5.96
6.04
mmol/l
1.26
1067
12182
217
1189
1.95
16.93
2.3
3.2
10.81
10.76
g/l
0.05
194
1104
33
62
5.41
16.87
1.1
1.0
14.82
247.99
ng/l
—
6
17
881
7016
1.53
16.29
4.6
5.4
35.82
35.15
g/l
3.05
831
6579
196
1056
1.97
16.03
5.9
7.3
26.65
24.51
mmol/l
7.14
188
1014
52
159
3.34
14.15
1.1
1.9
—
2306.67
—
0
6
21
12
17.70
13.84
1.0
1.0
—
—
—
0
0
134
669
2.09
13.50
5.2
5.1
25.83
24.91
mmol/l
3.26
128
627
281
1791
1.68
13.09
6.1
8.1
94.41
95.28
%
1.08
272
1742
1377
14853
0.61
13.02
29.5
27.5
6.89
6.82
e9/l
0.34
1338
14477
1378
14852
0.61
12.77
29.8
27.6
133.50
134.49
g/l
1.73
1363
14667
1378
14850
0.61
12.72
30.2
28.0
39.79
40.13
%
1.42
1362
14655
1378
14850
0.61
12.72
29.4
27.3
30.37
30.41
pg
0.43
1361
14663
1378
14850
0.61
12.72
29.5
27.4
4.42
4.46
e12/l
2.00
1339
14477
1378
14847
0.61
12.64
29.4
27.4
91.42
91.42
fl
0.01
1361
14662
1378
14846
0.62
12.61
29.5
27.4
250.68
244.12
e9/l
3.37
1346
14529
350
4902
0.64
12.19
3.0
3.4
—
—
—
0
0
390
5246
0.67
10.86
3.7
3.5
83.81
47.70
mg/l
0.80
254
3451
21
22
9.65
10.75
1.1
1.0
—
—
—
0
0
99
487
2.10
10.40
5.2
6.9
1.23
1.37
mmol/l
0.38
86
433
1341
14441
0.66
10.38
13.0
12.9
27.34
26.21
u/l
1.23
1299
14012
938
7962
1.40
10.24
7.6
7.8
1.22
1.21
mmol/l
3.75
818
6866
50
183
2.78
10.08
1.4
1.1
—
—
—
0
0
406
5352
0.68
9.95
4.6
4.2
13.92
8.54
mg/mmol
0.81
261
3411
1367
14631
0.66
9.67
25.5
23.8
71.57
81.54
umol/l
14.49
1351
14441
378
2752
1.48
9.63
3.0
3.6
0.82
0.82
mmol/l
0.06
356
2599
74
336
2.26
9.51
5.8
4.9
3.44
2.69
mmol/l
1.28
66
227
419
5451
0.69
9.42
4.3
3.5
7.23
7.56
mmol/l
0.87
350
4602
19
37
5.18
9.37
1.0
1.5
—
14.17
%
—
0
6
388
2863
1.46
9.18
1.7
1.8
1124.16
1155.86
nmol/l
0.28
313
2162
84
408
2.11
9.14
2.8
2.2
137.94
128.92
g/l
2.97
72
328
885
10141
0.73
8.86
3.8
4.4
—
4209.37
—
0
24
274
1913
1.52
8.47
1.4
1.4
641.25
463.11
titre
0.76
64
424
255
3575
0.66
8.29
2.8
3.4
0.79
0.78
ug/l
0.08
182
2418
28
82
3.46
8.23
2.2
2.0
28.02
98.67
umol/l
—
5
7
458
5708
0.73
7.49
2.2
2.3
—
—
—
0
0
1313
14030
0.71
7.26
17.7
16.3
—
—
—
0
0
421
3303
1.37
6.75
1.6
1.8
54496372.08
27033395.98
pmol/l
0.31
367
2730
35
826
0.41
6.68
1.8
1.8
3.46
3.46
mmol/l
0.00
28
613
218
1533
1.48
6.45
6.4
7.5
1.18
1.39
mmol/l
3.83
207
1501
93
531
1.80
6.39
1.3
1.2
7.33
0.99
u/ml
—
6
34
31
114
2.75
6.29
1.1
1.0
292.00
307.70
ng/l
0.12
23
70
823
7167
1.29
6.13
7.4
7.1
1.21
1.21
mmol/l
1.69
759
6622
561
4661
1.30
5.94
1.7
1.8
20.63
20.02
nmol/l
0.45
493
3935
1030
11284
0.78
5.77
23.7
22.6
13.73
13.76
%
0.33
1022
11121
30
114
2.66
5.75
1.1
1.0
875.00
614.91
ng/l
2.40
17
69
1351
14265
0.74
5.61
24.1
22.0
3.95
4.00
mmol/l
8.96
1326
13967
1350
14245
0.74
5.45
24.1
21.8
139.61
139.65
mmol/l
0.23
1331
13969
856
7565
1.27
5.39
6.0
6.5
0.04
0.04
e9/l
0.98
746
6446
13
21
6.23
5.38
1.1
1.3
54.15
66.90
ug/l
0.98
13
21
867
7686
1.26
5.27
6.1
6.6
2.01
1.89
e9/l
0.28
760
6733
218
1594
1.42
5.25
2.3
2.4
0.21
0.21
g/l
0.60
209
1478
795
6980
1.26
5.23
2.2
2.2
93.47
94.82
pmol/l
0.33
449
3755
852
7544
1.26
5.21
6.0
6.5
0.58
0.60
e9/l
2.37
743
6426
1030
11204
0.79
4.93
25.7
23.8
331.79
332.16
g/l
0.61
1019
11130
558
4727
1.27
4.88
3.8
3.4
—
—
—
0
0
67
1134
0.57
4.82
1.9
2.1
3.50
3.51
ratio
0.03
60
925
44
219
2.04
4.64
1.0
1.1
18.65
78.43
iu/ml
0.75
17
35
150
1047
1.47
4.63
6.7
9.2
25.87
24.21
mmol/l
6.52
144
1026
869
7795
1.24
4.44
6.2
6.8
0.18
0.19
e9/l
2.58
768
6771
836
7487
1.23
4.28
15.0
17.6
1.27
1.31
inr
1.14
695
6282
516
5995
0.80
4.25
5.0
5.8
8.48
3.66
ug/l
0.88
455
5393
48
857
0.55
4.20
1.2
1.4
—
—
—
0
0
18
62
2.92
4.17
2.4
1.7
42.12
39.55
g/l
1.17
18
62
227
1742
1.35
4.08
4.8
4.2
3.21
1.85
mmol/l
5.55
209
1474
15
47
3.21
4.06
1.0
1.1
—
—
—
0
0
15
47
3.21
4.06
1.0
1.1
—
—
—
0
0
15
47
3.21
4.06
1.0
1.1
—
—
—
0
0
552
4785
1.23
3.73
4.1
4.4
7.40
7.40
ph
0.16
390
3484
543
4701
1.23
3.71
4.5
4.6
—
—
—
0
0
782
7022
1.21
3.70
6.0
6.8
0.65
0.67
%
0.48
748
6547
16
402
0.39
3.67
1.3
1.2
—
—
—
0
0
782
7027
1.21
3.66
6.1
6.8
8.65
9.06
%
4.50
746
6559
231
1807
1.32
3.65
4.6
4.3
7.37
7.38
ph
0.52
132
1067
64
391
1.66
3.59
1.8
1.7
—
—
—
0
0
51
293
1.76
3.56
1.2
1.2
38.23
53.39
u/ml
—
6
33
230
1805
1.32
3.56
4.7
4.2
6.20
5.82
kpa
4.31
224
1751
22
477
0.45
3.51
1.2
1.7
—
—
—
0
0
64
396
1.64
3.43
2.8
3.1
31.31
36.61
umol/l
0.84
58
348
13
347
0.37
3.43
1.0
1.2
1.42
1.54
g/l
0.91
13
347
778
7017
1.20
3.43
6.0
6.7
2.60
2.84
%
2.46
743
6544
141
1039
1.39
3.29
4.8
4.6
25.66
24.14
mmol/l
5.98
141
1024
1317
13761
0.81
3.25
21.0
18.2
26.46
26.31
mg/l
0.05
1156
11515
37
199
1.88
3.22
1.3
2.1
—
9.60
—
0
5
343
4060
0.81
3.18
3.1
3.0
348.02
354.19
umol/l
0.46
302
3552
194
1516
1.32
3.11
4.4
3.7
4.56
4.52
kpa
0.10
188
1469
786
7140
1.19
3.09
6.0
6.7
26.29
26.79
%
0.60
754
6746
85
578
1.50
3.07
2.0
1.8
9.16
7.45
iu/ml
0.23
17
133
53
323
1.66
3.05
1.5
1.4
57.76
60.98
mmol/l
0.25
42
263
153
1992
0.75
3.04
1.3
1.3
—
—
—
0
0
584
5174
1.20
3.03
5.5
6.6
—
—
—
0
0
61
387
1.60
3.00
1.3
1.2
2.63
2.47
u/ml
—
8
34
475
5408
0.83
2.94
4.0
3.9
—
0.71
—
0
21
130
967
1.37
2.90
9.2
10.6
17.12
15.87
%
6.80
124
936
766
6994
1.17
2.72
5.9
6.6
58.76
57.87
%
1.22
743
6660
969
9018
1.17
2.71
5.8
5.5
6.65
6.79
mmol/l
1.45
929
8626
362
3095
1.22
2.71
1.4
1.3
1.37
1.64
u/ml
0.18
93
810
188
2341
0.78
2.69
1.3
1.3
4.34
12.56
u/ml
3.26
74
851
64
938
0.67
2.57
1.2
1.3
—
—
—
0
0
105
774
1.38
2.51
4.4
5.6
1.57
1.58
%
0.03
97
735
43
669
0.63
2.32
1.2
1.3
—
—
—
0
0
42
652
0.64
2.25
3.0
3.4
4392.48
6342.16
u/ml
0.13
36
562
105
791
1.35
2.22
4.0
3.4
25.88
25.19
mmol/l
0.96
98
762
268
2269
1.22
2.21
6.0
6.3
1.04
1.05
mmol/l
0.20
252
2099
26
144
1.82
2.15
1.2
1.2
—
—
—
0
0
234
1963
1.22
2.12
1.6
1.7
—
—
—
0
0
79
574
1.39
2.10
4.0
3.5
290.18
282.46
mg/l
0.04
33
242
184
1509
1.25
2.06
9.0
8.9
—
—
—
0
0
217
1813
1.23
2.05
2.0
1.8
—
—
—
0
0
27
154
1.77
2.04
2.1
2.1
—
—
—
0
0
21
111
1.90
2.01
1.3
1.5
1.51
1.04
promille
0.53
16
88
1227
12757
0.86
2.00
5.2
5.3
1.89
1.98
mu/l
1.68
1144
11677
93
706
1.34
1.90
4.4
5.9
0.89
0.87
%
0.15
85
670
142
1748
0.80
1.88
3.3
4.3
10.79
19.36
ug/l
0.62
115
1450
32
197
1.64
1.87
2.1
2.5
1.27
1.45
g/24h
0.11
15
116
899
8453
1.14
1.86
7.9
10.1
4.20
4.21
e9/l
0.04
780
7326
29
175
1.67
1.83
1.2
1.2
—
—
—
0
0
17
87
1.96
1.80
2.7
2.9
—
—
—
0
0
26
420
0.61
1.72
1.2
1.1
—
—
—
0
0
13
62
2.11
1.65
1.2
1.1
1704.54
1597.87
miu/ml
0.08
13
62
172
1438
1.22
1.65
2.0
2.2
384.49
375.90
nmol/l
0.25
154
1342
20
112
1.80
1.64
1.8
2.4
8.48
8.03
mmol/l
0.14
20
112
111
1378
0.79
1.60
2.1
2.4
13.72
13.27
nmol/l
0.21
96
1234
6
20
3.01
1.58
1.2
3.2
—
—
—
0
0
29
183
1.59
1.57
1.6
1.5
273.86
277.73
mosm/kgh2o
0.31
22
135
360
4011
0.87
1.57
3.4
3.2
0.17
0.02
0.40
12
103
178
1502
1.21
1.56
4.7
4.5
7.37
7.36
ph
0.48
137
1085
581
5362
1.13
1.56
2.7
3.5
2.37
2.35
mmol/l
1.55
516
4827
0
42
0.00
1.52
0.0
1.3
—
28.12
—
0
42
18
308
0.58
1.52
1.1
1.3
—
—
—
0
0
11
51
2.16
1.50
1.4
1.4
—
—
—
0
0
617
6628
0.89
1.50
3.1
3.1
158.73
144.12
ug/l
0.38
564
6121
140
1677
0.82
1.47
1.3
1.4
—
—
—
0
0
8
170
0.47
1.46
1.0
1.1
—
—
—
0
0
40
279
1.44
1.41
1.2
1.4
—
9.50
—
0
6
29
189
1.54
1.40
1.3
1.6
19.97
30.36
ng/l
0.90
29
189
0
38
0.00
1.34
0.0
7.8
—
5.09
—
0
38
132
1104
1.21
1.30
1.2
1.2
—
—
—
0
0
11
206
0.53
1.30
1.0
1.3
—
—
—
0
0
724
7654
0.91
1.24
4.6
4.0
0.00
0.00
estimate
-0.00
158
1638
42
572
0.73
1.24
1.1
1.1
—
—
—
0
0
93
755
1.25
1.23
1.3
1.6
—
—
—
0
0
74
586
1.27
1.20
2.5
1.7
0.42
0.33
mg/l
0.45
33
273
21
132
1.60
1.20
1.1
1.1
—
—
—
0
0
526
4891
1.11
1.20
3.7
3.4
33.98
37.97
u/l
0.49
505
4622
72
572
1.27
1.15
1.2
1.2
—
—
—
0
0
18
284
0.63
1.15
1.6
1.7
—
—
—
0
0
737
7761
0.91
1.14
4.7
4.1
0.00
2.95
estimate
1.07
158
1669
7
30
2.34
1.12
1.7
1.1
—
—
—
0
0
5
21
2.38
1.09
5.2
6.6
6.00
8.71
%
—
5
21
5
21
2.38
1.09
2.6
3.3
36.00
43.52
%
—
5
21
83
1012
0.81
1.09
1.3
1.4
—
—
—
0
0
342
3123
1.12
1.08
4.7
5.0
—
—
—
0
0
10
52
1.93
1.06
1.2
1.1
1.57
10.77
u/ml
—
5
9
30
418
0.71
1.05
2.2
1.6
13608.64
16377.06
e6/l
0.14
22
296
17
106
1.61
1.03
1.8
1.8
—
—
—
0
0
7
34
2.06
1.03
1.0
1.4
—
183.00
—
0
6
744
7801
0.92
1.01
4.7
4.1
0.03
0.21
estimate
0.44
150
1556
31
222
1.40
1.01
4.9
5.6
368.86
353.50
umol/l
0.21
25
202
127
1475
0.85
1.00
3.2
2.5
32.46
71.86
u/l
0.63
106
1233
12
201
0.59
1.00
1.2
1.1
—
—
—
0
0
12
200
0.60
0.98
1.2
1.1
—
—
—
0
0
0
29
0.00
0.97
0.0
1.1
—
—
—
0
0
7
36
1.95
0.97
1.7
1.6
—
—
—
0
0
304
2780
1.11
0.95
1.4
1.5
2.38
2.58
g/l
0.93
191
1662
999
9647
1.09
0.94
5.9
5.0
2899.06
1631.23
e6/l
0.27
18
151
19
125
1.53
0.94
2.3
2.3
568.43
657.68
ml
0.51
14
81
21
300
0.70
0.88
1.1
1.3
276.56
212.29
miu/ml
—
9
125
7
130
0.54
0.88
2.3
2.5
—
—
—
0
0
34
256
1.33
0.85
1.8
1.8
4.89
4.70
mmol/24h
0.11
28
227
487
5158
0.92
0.81
2.9
3.3
1347.69
1544.85
ng/l
0.36
408
4461
28
373
0.75
0.79
2.6
3.4
398.33
1061.17
u/ml
0.42
28
353
8
48
1.67
0.78
4.0
3.9
—
—
—
0
0
13
199
0.65
0.78
1.2
1.4
—
—
—
0
0
6
34
1.77
0.76
1.3
1.2
—
—
—
0
0
166
1846
0.89
0.75
1.5
1.5
—
—
—
0
0
425
4510
0.92
0.74
5.9
6.6
—
—
—
0
0
17
116
1.47
0.74
1.1
1.1
103.12
104.47
pmol/l
0.05
17
116
73
616
1.19
0.74
3.1
3.8
34.18
66.21
mg/l
0.99
61
529
143
1273
1.13
0.73
3.0
4.0
1.22
1.22
mmol/l
0.40
116
1098
9
55
1.64
0.73
2.2
1.7
—
—
—
0
0
161
1790
0.89
0.73
3.3
3.2
7.74
8.17
umol/l
0.12
138
1612
7
39
1.80
0.72
1.3
1.5
—
—
—
0
0
10
60
1.67
0.72
3.0
2.3
9.40
10.91
%
—
10
54
32
410
0.78
0.70
1.0
1.1
—
—
—
0
0
9
142
0.63
0.69
1.0
1.2
—
—
—
0
0
31
239
1.30
0.69
2.7
2.9
—
—
—
0
0
19
262
0.72
0.69
5.6
4.1
2.84
1.47
%
0.52
19
244
118
1330
0.88
0.68
1.3
1.4
—
—
—
0
0
5
92
0.54
0.67
1.6
3.6
4.00
20.54
umol/l
—
5
67
152
1371
1.12
0.65
3.2
2.5
1.41
0.46
e6/l
0.47
146
1311
72
616
1.18
0.65
3.1
3.8
44.69
58.82
mg/l
0.66
61
528
122
1366
0.88
0.64
1.7
1.5
—
—
—
0
0
23
303
0.76
0.63
1.5
1.7
—
—
—
0
0
30
381
0.78
0.63
4.0
3.5
0.84
0.82
nmol/l
0.11
25
312
382
4042
0.93
0.62
3.9
3.6
0.02
0.04
estimate
0.52
127
1282
77
887
0.86
0.61
1.2
1.3
376.87
220.97
u/ml
0.68
70
812
8
51
1.57
0.60
2.4
2.4
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
52.24
—
0
21
8
52
1.54
0.59
1.3
1.9
17.13
31.85
%
—
8
52
102
1146
0.88
0.58
3.2
2.8
6.12
6.06
ph
0.34
82
803
20
149
1.35
0.57
4.5
2.6
—
—
—
0
0
594
6175
0.94
0.57
4.1
3.6
6.38
6.24
ph
2.32
332
3430
83
729
1.15
0.56
2.3
2.1
0.00
1.21
estimate
0.50
17
208
10
65
1.54
0.55
1.1
1.2
—
—
—
0
0
155
1694
0.91
0.55
2.4
2.4
140.01
134.61
ug/g
0.09
113
1360
6
38
1.58
0.54
1.0
1.1
—
—
—
0
0
25
317
0.79
0.54
4.0
1.9
—
—
—
0
0
84
950
0.88
0.54
1.5
1.4
—
—
—
0
0
30
240
1.25
0.54
2.4
2.7
—
—
—
0
0
342
3236
1.07
0.53
2.7
3.1
2.46
2.46
mmol/l
0.41
302
2890
148
1353
1.10
0.52
2.6
3.4
161.32
226.42
ng/l
1.25
142
1257
17
126
1.35
0.51
1.1
1.2
—
—
—
0
0
829
8066
1.05
0.51
6.1
6.9
11.56
12.15
umol/l
0.53
794
7706
61
700
0.87
0.49
2.8
2.7
—
—
—
0
0
10
144
0.69
0.49
1.1
1.2
—
—
—
0
0
123
1349
0.90
0.48
4.3
4.3
1.34
0.69
%
0.54
34
439
464
4832
0.95
0.47
3.1
2.7
53.74
77.99
u/l
0.84
435
4475
156
1687
0.92
0.46
1.6
1.6
—
—
—
0
0
197
1838
1.08
0.46
3.3
3.4
5.13
4.95
e9/l
0.10
165
1584
28
342
0.82
0.46
3.6
3.1
59.11
58.75
%
0.05
28
342
558
5773
0.95
0.44
5.0
4.3
160.86
108.61
e6/l
0.45
421
4197
31
256
1.21
0.44
2.5
2.1
0.84
0.89
%
0.27
25
189
237
2513
0.93
0.43
1.3
1.3
30.93
32.15
iu/ml
0.05
57
788
8
56
1.43
0.42
3.5
2.7
0.61
0.60
mmol/l
—
8
56
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
7.30
—
0
9
83
748
1.12
0.41
2.2
2.0
0.53
1.94
ug/l
2.62
74
667
361
3769
0.95
0.41
2.4
2.6
—
—
—
0
0
13
172
0.75
0.40
1.8
4.7
—
—
—
0
0
8
60
1.33
0.40
1.6
1.1
98.38
176.16
iu/ml
—
8
60
680
6617
1.05
0.40
2.6
2.5
77.98
77.78
nmol/l
0.06
606
5908
171
1828
0.93
0.40
4.4
5.2
32.04
32.58
%
0.28
113
1183
108
1177
0.91
0.39
4.5
4.1
—
—
—
0
0
7
102
0.69
0.39
1.4
1.5
—
—
—
0
0
7
105
0.67
0.39
1.4
1.6
—
—
—
0
0
49
430
1.14
0.37
1.1
1.2
—
9.91
—
0
8
5
37
1.35
0.37
2.8
1.8
85.40
88.70
nmol/24h
—
5
37
376
3909
0.95
0.37
1.3
1.4
—
—
—
0
0
65
724
0.89
0.37
1.4
1.3
—
—
—
0
0
104
957
1.09
0.36
1.9
1.9
1.80
1.42
g/l
0.32
92
884
70
631
1.11
0.36
1.0
1.1
—
142.87
—
0
16
71
785
0.90
0.35
3.8
3.7
1.02
1.02
ratio
0.15
66
725
559
5752
0.96
0.35
4.7
4.0
0.03
0.02
estimate
0.07
136
1363
357
3432
1.05
0.35
4.8
4.2
1.02
1.02
kg/l
0.15
248
2324
9
122
0.74
0.35
2.3
1.6
—
—
—
0
0
50
442
1.14
0.35
7.9
11.1
—
—
—
0
0
14
177
0.79
0.33
1.1
1.3
—
—
—
0
0
402
3883
1.05
0.33
5.0
4.5
88.01
86.40
%
0.75
394
3805
6
89
0.67
0.33
1.3
1.2
—
—
—
0
0
76
831
0.91
0.32
1.7
1.8
1.54
1.52
g/l
0.06
69
730
14
176
0.79
0.32
1.2
1.1
1.03
2.16
u/ml
—
7
94
633
6480
0.96
0.31
11.8
12.4
0.00
0.00
e9/l
1.77
508
5256
7
97
0.72
0.31
1.1
1.2
9.53
9.28
mmol/l
—
7
92
7
100
0.70
0.30
3.6
2.7
49.86
38.57
%
—
7
55
8
109
0.73
0.29
1.4
2.6
12.50
19.16
nmol/l
—
8
99
19
227
0.84
0.28
1.1
1.1
1.59
1.52
g/l
0.49
19
207
447
4346
1.04
0.28
4.9
4.1
0.00
0.00
estimate
0.96
142
1492
5
71
0.70
0.26
1.4
1.2
122.74
415.73
u/l
—
5
63
32
282
1.14
0.25
1.5
1.2
—
—
—
0
0
61
560
1.09
0.25
1.8
2.6
20.67
21.35
s
0.40
52
513
23
266
0.86
0.25
1.5
1.5
144.33
143.05
au/ml
—
9
82
17
142
1.20
0.24
5.5
1.8
2.19
4.68
mg/l
5.86
17
137
37
413
0.89
0.24
1.2
1.3
—
—
—
0
0
22
254
0.86
0.23
3.9
2.0
—
—
—
0
0
221
2296
0.96
0.23
1.9
2.1
—
—
—
0
0
15
179
0.84
0.23
1.3
1.2
—
—
—
0
0
17
200
0.85
0.22
1.1
1.4
—
—
—
0
0
60
554
1.09
0.22
2.9
3.7
1.67
3.60
ratio
1.16
32
330
28
316
0.88
0.22
3.6
2.0
—
—
—
0
0
7
93
0.75
0.22
1.4
1.9
59.26
114.90
ng/l
—
7
93
5
40
1.25
0.22
1.4
3.1
4.20
5.47
ug/l
—
5
40
483
4938
0.97
0.22
2.4
2.6
—
—
—
0
0
37
410
0.90
0.22
1.5
1.2
—
—
—
0
0
5
41
1.22
0.22
1.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
0.12
—
0
6
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
5.48
—
0
12
51
469
1.09
0.21
1.5
1.6
16.24
17.84
u/ml
—
7
94
77
721
1.07
0.21
2.1
2.0
—
—
—
0
0
13
108
1.21
0.20
1.2
1.3
—
—
—
0
0
38
417
0.91
0.20
1.4
1.4
42.01
27.41
iu/l
1.23
33
342
138
1442
0.95
0.19
1.6
1.6
—
—
—
0
0
41
376
1.09
0.18
1.1
1.2
—
—
—
0
0
18
156
1.16
0.18
1.1
1.2
—
—
—
0
0
54
503
1.08
0.18
7.0
5.0
1.60
1.64
mg/l
0.11
54
454
131
1256
1.05
0.17
4.7
4.2
90.07
95.75
ng/l
0.30
118
1088
18
157
1.15
0.17
1.3
1.2
1.26
1.45
nmol/l
0.37
13
140
905
9143
0.98
0.16
3.9
3.5
45.65
54.25
u/l
1.58
851
8530
23
256
0.90
0.16
1.4
1.5
117.04
295.48
pmol/l
1.22
23
251
29
318
0.91
0.16
3.5
2.0
—
—
—
0
0
30
328
0.91
0.15
1.9
1.9
5.55
21.83
iu/l
0.45
13
132
20
178
1.13
0.15
1.7
2.4
—
—
—
0
0
320
3133
1.03
0.15
3.6
3.1
511.25
538.03
mosm/kgh2o
1.51
280
2756
207
2127
0.97
0.14
1.3
1.3
—
—
—
0
0
29
316
0.92
0.14
3.5
2.0
—
—
—
0
0
16
181
0.88
0.14
1.1
1.2
—
—
—
0
0
22
243
0.90
0.14
1.1
1.1
—
—
—
0
0
257
2628
0.97
0.13
3.9
3.4
2.70
1.94
e6/l
0.44
148
1354
37
344
1.08
0.13
1.3
1.4
10.89
8.69
u/l
0.47
29
265
35
376
0.93
0.13
2.8
2.4
89.94
103.01
ug/min
0.07
18
226
682
6894
0.98
0.13
2.6
2.9
—
—
estimate
—
0
0
261
2555
1.03
0.13
2.5
2.3
29.58
29.81
s
0.32
253
2478
1056
10630
0.98
0.12
4.1
4.2
15.19
14.93
pmol/l
2.66
980
9654
131
1351
0.97
0.12
4.8
4.8
0.06
0.13
%
0.63
33
370
15
133
1.13
0.12
1.3
1.4
11.47
13.66
u/l
0.91
15
126
85
817
1.04
0.12
2.6
2.4
—
—
—
0
0
13
147
0.88
0.11
2.2
2.2
—
—
—
0
0
14
157
0.89
0.11
1.1
1.1
3.12
4.23
u/ml
—
9
81
19
208
0.91
0.10
1.2
1.4
15013.57
105872.36
e6/l
1.72
14
117
284
2793
1.02
0.10
2.6
2.7
13.21
12.52
umol/l
0.77
257
2607
201
2051
0.98
0.10
2.3
2.8
1.71
1.80
%
0.79
184
1831
5
44
1.14
0.10
1.0
1.2
—
—
—
0
0
5
45
1.11
0.09
1.0
1.0
—
—
—
0
0
81
782
1.04
0.09
2.4
3.5
4.36
4.46
pmol/l
0.39
73
689
524
5187
1.01
0.09
4.3
3.6
42.06
92.18
e6/l
1.95
414
4040
369
3643
1.02
0.09
3.3
2.8
5.84
5.21
e6/l
0.34
340
3333
157
1605
0.98
0.09
8.6
7.4
9.51
10.54
mmol/l
1.02
151
1541
18
196
0.92
0.09
1.3
1.6
—
—
—
0
0
28
298
0.94
0.08
3.6
2.0
—
—
—
0
0
30
318
0.94
0.08
5.6
3.7
22.07
28.16
mg/l
0.78
23
225
5
62
0.81
0.08
1.0
1.3
156.70
179.37
mmol/24h
—
5
62
21
226
0.93
0.08
1.2
1.1
5.61
1.84
u/ml
0.38
13
136
24
224
1.07
0.08
7.6
2.8
—
—
—
0
0
16
146
1.10
0.08
1.3
1.3
—
—
—
0
0
6
71
0.84
0.07
1.2
1.3
—
1.43
%
—
0
14
17
184
0.92
0.07
1.1
1.1
1.55
1.93
u/ml
—
6
88
28
296
0.95
0.07
1.5
1.5
—
—
—
0
0
8
91
0.88
0.06
1.1
1.1
—
6.78
—
0
18
12
131
0.92
0.05
1.6
1.9
—
—
—
0
0
241
2436
0.99
0.05
2.6
2.7
23.75
22.35
%
0.86
221
2277
146
1439
1.02
0.05
2.6
2.4
7.21
7.06
ug/l
0.02
131
1267
162
1600
1.01
0.04
2.5
2.8
65.86
69.27
e9/l
0.83
123
1187
450
4473
1.01
0.04
4.1
3.5
0.53
0.46
e6/l
0.29
348
3354
142
1439
0.99
0.04
2.1
2.1
0.00
0.02
estimate
0.78
19
280
317
3146
1.01
0.04
3.9
4.2
395.62
417.98
ng/l
0.03
263
2601
24
229
1.05
0.04
1.4
1.6
—
—
—
0
0
24
229
1.05
0.04
1.4
1.6
—
—
—
0
0
24
229
1.05
0.04
1.4
1.6
—
—
—
0
0
24
229
1.05
0.04
1.4
1.6
—
—
—
0
0
319
3213
0.99
0.04
1.8
1.8
1.27
1.37
mg/l
0.22
249
2519
29
279
1.04
0.04
1.2
1.4
254.44
274.98
u/ml
0.24
16
147
132
1337
0.99
0.04
4.6
4.6
0.17
0.11
%
0.26
35
388
21
200
1.05
0.03
1.2
1.2
1.89
5.55
u/ml
—
9
91
12
129
0.93
0.03
1.3
1.4
42.80
28.18
%
—
5
79
47
482
0.97
0.03
1.4
1.5
257.16
272.67
ug/g
0.27
32
297
16
151
1.06
0.03
2.4
3.7
12.75
11.53
index
—
8
90
26
270
0.96
0.03
3.3
3.2
4.26
4.35
e9/l
0.06
26
270
17
179
0.95
0.03
2.4
2.5
—
—
—
0
0
420
4220
0.99
0.03
2.3
2.4
2.89
2.89
mg/l
0.01
355
3622
12
112
1.07
0.03
1.0
1.1
—
—
—
0
0
40
390
1.03
0.02
4.3
4.8
—
—
—
0
0
13
138
0.94
0.02
1.1
1.1
—
—
—
0
0
19
182
1.04
0.02
1.4
1.6
41.20
62.93
%
—
10
114
260
2614
0.99
0.02
2.5
2.7
2.26
2.27
g/l
0.14
233
2420
19
198
0.96
0.02
1.2
1.4
0.67
9.69
nmol/l
0.50
19
188
284
2826
1.01
0.02
3.6
3.2
0.97
1.07
e6/l
0.27
177
1558
1128
11296
1.00
0.02
8.3
8.6
77.10
81.21
u/l
2.48
1072
10704
142
1409
1.01
0.02
4.4
4.5
1.20
0.90
%
0.48
44
460
11
103
1.07
0.02
1.0
1.1
—
—
—
0
0
16
153
1.05
0.01
1.0
1.1
1.00
2.63
eliau/ml
—
6
51
17
177
0.96
0.01
1.3
1.3
—
—
—
0
0
10
94
1.06
0.01
1.4
1.5
128.14
160.42
pmol/l
—
10
94
11
104
1.06
0.01
1.1
1.2
—
—
—
0
0
11
104
1.06
0.01
1.4
1.4
7.34
7.39
ph
0.23
11
75
16
166
0.96
0.00
1.2
1.3
—
—
—
0
0
605
6043
1.00
0.00
4.6
4.2
43.99
77.47
ng/l
1.20
504
4566
422
4226
1.00
0.00
3.8
3.5
—
0.00
estimate
—
0
19
11
105
1.05
0.00
1.8
2.3
3.47
3.00
ug/l
0.15
11
100
14
139
1.01
0.00
1.1
1.2
8.64
13.21
u/l
0.89
14
126
44
441
1.00
0.00
3.2
3.5
2.14
1.77
index
0.15
22
241
19
186
1.02
0.00
1.1
1.1
5.09
5.04
u/ml
—
9
104
23
234
0.98
0.00
5.5
6.8
11.58
12.44
mg/l
0.43
23
219
14
137
1.02
0.00
1.7
1.7
—
—
—
0
0
24
237
1.01
0.00
1.0
1.1
—
—
—
0
0
79
795
0.99
0.00
1.1
1.2
130.93
145.95
u/ml
0.11
24
306
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
0.00
0.0
4.7
—
—
—
0
0
0
9
0.00
0.00
0.0
2.0
—
146.33
—
0
9
0
9
0.00
0.00
0.0
1.0
—
163.11
—
0
9
0
9
0.00
0.00
0.0
2.3
—
—
—
0
0
10
100
1.00
-0.00
1.3
1.5
77.00
88.69
umol/l
—
10
100
0
5
0.00
-0.00
0.0
1.0
—
1745.20
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
9
90
1.00
-0.00
1.2
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.2
—
98.00
—
0
6
8
87
0.92
-0.00
1.1
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
361.43
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
30.86
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
72.73
—
0
6
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
63
0.95
-0.00
1.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
-0.00
1.2
2.5
11.94
180.78
ug/l
—
5
43
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
7
76
0.92
-0.00
1.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

Association

Association between endpoint G6_NEUATR and mortality.

Females

Parameter HR [95% CI] p-value
G6_NEUATR 7.442 [6.44, 8.6] < 0.001
Birth year 0.994 [0.99, 1.0] 0.176

During the follow-up period (1.1.1998 — 31.12.2019), 2750 out of 4587 females with G6_NEUATR died.

Males

Parameter HR [95% CI] p-value
G6_NEUATR 5.431 [4.76, 6.19] < 0.001
Birth year 0.986 [0.98, 1.0] 0.006

During the follow-up period (1.1.1998 — 31.12.2019), 3012 out of 5076 males with G6_NEUATR died.

Mortality risk

Mortality risk for people of age

years, who have G6_NEUATR.

N-year risk Females Males
1 0.823% 0.863%
5 3.911% 5.649%
10 10.404% 14.121%
15 19.039% 26.114%
20 31.816% 40.692%

Relationships between endpoints

Index endpoint: G6_NEUATR – Systemic atrophies primarily affecting the central nervous system

GWS hits: 13

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data